

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4254620

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HERRIOT TABUTEAU	06/14/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ANTECIP BIOVENTURES II LLC
<b>Street Address:</b>	630 FIFTH AVENUE, SUITE 2000
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10111
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15356434
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(949)253-0902
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	949-253-0900
<b>Email:</b>	maria.nadal@klgates.com
<b>Correspondent Name:</b>	BRENT A. JOHNSON, PH.D.
<b>Address Line 1:</b>	K&L GATES LLP
<b>Address Line 2:</b>	1 PARK PLAZA - 12TH FLOOR
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92614
<b>ATTORNEY DOCKET NUMBER:</b>	1958603.00225
<b>NAME OF SUBMITTER:</b>	BRENT A. JOHNSON
<b>SIGNATURE:</b>	/Brent A. Johnson/
<b>DATE SIGNED:</b>	02/01/2017
<b>Total Attachments: 8</b>	
source=1958603.EXECUTED ASSIGNMENT#page1.tif	
source=1958603.EXECUTED ASSIGNMENT#page2.tif	
source=1958603.EXECUTED ASSIGNMENT#page3.tif	
source=1958603.EXECUTED ASSIGNMENT#page4.tif	
source=1958603.EXECUTED ASSIGNMENT#page5.tif	

source=1958603.EXECUTED ASSIGNMENT#page6.tif

source=1958603.EXECUTED ASSIGNMENT#page7.tif

source=1958603.EXECUTED ASSIGNMENT#page8.tif

## ASSIGNMENT

**THIS ASSIGNMENT** is made by Herriot Tabuteau (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNOR") to Antecip Bioventures II LLC, a limited liability corporation duly organized and existing under and by the laws of the State of Delaware and having its principal place of business at 630 Fifth Avenue, Suite 2000, New York, New York 10111, (hereafter, together with any successors, legal representatives, or assigns thereof, "ASSIGNEE").

**WHEREAS**, ASSIGNOR has invented and owns rights in, to and under new and useful inventions for which an applications for Letters Patent has been filed as indicated in attached Appendix A (hereafter "Inventions");

**WHEREAS**, ASSIGNOR believes himself to be the original and true inventor of the Inventions;

**WHEREAS**, ASSIGNEE desires to acquire the Inventions and improvements thereto;

**AND WHEREAS**, ASSIGNOR and ASSIGNEE desire to have a recordable instrument assigning ASSIGNEE as owners of the entire right, title and interest in, to, and under the Invention and improvements thereto owned by ASSIGNOR;

**NOW THEREFORE**, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign, transfer, convey, endorse, and hereby set over unto ASSIGNEE the full and exclusive right, title and interest in, to and under the Inventions to be held and enjoyed by ASSIGNEE, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made including the full and exclusive right, title and interest in, to and under 1) any patent application, or any other legal instrument equivalent thereof, including, without limitation, continuation, division, continuation-in-part, substitute, reexamination, renewal, inventor's certificate, and utility model, which has been or may be submitted therefor and thereon anywhere in the World, such term defined herein as including the United States of America, its territorial possessions, and any and all foreign countries under national laws or under the provisions of the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or any other international treaty equivalent thereof; 2) any Letters Patent, or any other legal instrument equivalent thereof, which has been or may be granted therefor and thereon, in the World, for the full term or terms for which the same may be granted; 3) any reissue, extension, or any other legal instrument equivalent thereof, on any patent application or Letters Patent which has been or may be granted therefor and thereon in the World; and 4) any right to claim priority to a filing date, or any other legal equivalent thereof, which has been or may be claimed by any patent application or Letters Patent therefor and thereon in the World.

ASSIGNOR hereby covenants and agrees to perform any lawful action when deemed essential by and to ASSIGNEE's full enjoyment, protection, enforcement and title in, to and under the Inventions and rights hereby transferred, including, but not limited to, promptly communicating and providing any and all known and accessible facts, data or any other pertinent information; promptly executing and delivering any and all papers, documents, forms, declarations, oaths, affidavits or any other legal instrument; promptly assisting and participating in any and all depositions, hearings, proceedings, trials, appeals, or any other legal procedure; promptly testifying under oath in any and all interference, post grant review, litigation or any other administrative or judicial proceeding; and promptly completing any and all actions necessary or


desirable to carry out any and all purposes thereof, relating to any and all proceedings in connection with the submission, procurement, issuance, maintenance, enforcement or defense of the inventions and rights hereby transferred.

The undersigned hereby grant to the firm of K&L Gates LLP, 1 Park Plaza, 12th Floor, Irvine, CA 92614, the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment

IN TESTIMONY WHEREOF, I hereunder set my hand this 14 day of June, 2016.  
IN TESTIMONY WHEREOF, I hereunder set my hand this 14 day of June, 2016.

**ASSIGNOR**

Herriot Tabuteau  
Printed Name

  
Signature 06-14-2016.


State of New York )  
County of New York ) ss.:

On this 14 day of June, 2016, before me, Dan Yeager,  
~~Herriot Tabuteau~~  
personally appeared Herriot Tabuteau, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his authorized capacity and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of New York that the foregoing paragraph is true and correct.

Witness my hand and official seal.

**ILAN B YARDEN**  
Notary Public - State of New York  
No. 01YAG202005  
Qualified in Queens County  
My Commission Expires May 20, 2017

  
Notary Public

**APPENDIX A**  
**PATENT RIGHTS: PATENTS AND PATENT APPLICATIONS**

Title	Application Serial No.
PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPOIN AND MOXONIDINE	61/611,189
PHARMACEUTICAL COMPOSITIONS COMPRISING NALBUPHINE AND NAPROXEN	61/616,638
COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	61/624,694
PHARMACEUTICAL COMPOSITIONS COMPRISING NALBUPHINE AND CELECOXIB OR RELATED COMPOUNDS	61/635,319
USE OF PAMIDRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	61/646,538
USE OF PAMIDRONATE, OLPADRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	61/647,478
USE OF INCADRONATE AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	61/654,292
USE OF BISPHOSPHONATES FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS AND OTHER DISORDERS	61/654,383
ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS AND OTHER DISORDERS	61/655,527
USE OF ZOLEDRONIC ACID AND RELATED COMPOUNDS FOR THE TREATMENT OF PAIN	61/762,225
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	61/900,354
BISPHOSPHONATE COMPOUNDS FOR TREATING DISEASE	61/933,608
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	62/053,619
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM AND CYCLODEXTRINS	62/114,215
METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	62/116,609
METHODS FOR SAFELY ADMINISTERING OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	62/117,797
PHARMACODYNAMIC EFFECTS AFTER ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	62/150,871
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	62/259,993
METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	62/313,067
METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	62/313,620
METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	62/323,438

METHODS OF MODULATING DRUG PLASMA LEVELS	62/336,533
IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	13/468,215
COMPOSITIONS AND METHODS COMPRISING TILIDINE OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	13/478,023
COMPOSITIONS AND METHODS COMPRISING TILIDINE OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	13/857,017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	13/894,244
COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING PAIN ASSOCIATED WITH ARTHRITIS	13/894,252
COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	13/894,262
COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	13/894,274
COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	13/943,729
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/063,979
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/106,291
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/279,196
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MUSCULOSKELETAL PAIN	14/279,206
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING ANKYLOSING SPONDYLITIS	14/279,213
TREATMENT OF ARTHRITIS USING DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	14/279,222
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MULTIPLE MYELOMA	14/279,226
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN	14/279,229
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	14/279,232
TREATING DISEASE USING COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	14/279,236
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/279,241
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	14/288,241
SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	14/288,713

SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	14/288,716
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/310,811
ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	14/329,844
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	14/336,642
SUBSTITUTED IMIDAZOLIUM COMPOUNDS FOR TREATING DISEASE	14/446,184
TREATMENT OF PAIN WITH ORAL DOSAGE FORMS COMPRISING ZOLEDRONIC ACID AND AN ENHANCER	14/456,939
ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	14/457,659
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	14/481,097
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	14/495,732
CO-ADMINISTRATION OF STEROIDS AND ZOLEDRONIC ACID TO PREVENT AND TREAT PAIN	14/530,556
INHIBITORS OF OSTEOCLAST ACTIVITY FOR TREATING ARTHRITIS	14/536,526
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	14/538,709
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	14/540,333
COMPOSITIONS AND METHODS FOR REDUCING DEXTORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS	14/550,618
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	14/554,947
COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN	14/554,988
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	14/555,085
COMPOSITIONS AND METHODS OF USING THREOHYDROXYBUPROPION FOR THERAPEUTIC PURPOSES	14/602,177
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	14/604,397
HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS	14/617,624
METHODS FOR THE SAFE ADMINISTRATION OF IMIDAZOLE OR IMIDAZOLIUM COMPOUNDS	14/625,457
METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	14/628,062
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	14/635,857
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR	14/686,551

TREATING LOW BACK PAIN	
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	14/812,989
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	14/863,284
COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	14/878,980
COMPOSITIONS AND METHODS FOR REDUCING DEXTROPORPHAN PLASMA LEVELS AND RELATED PHARMACODYNAMIC EFFECTS	14/878,998
COMPOSITIONS AND METHODS COMPRISING ERYTHROHYDROXYBUPROPION AND RELATED COMPOUNDS FOR IMPROVING THE EFFICACY OF DEXTROMETHORPHAN	14/879,002
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	14/952,724
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	14/967,224
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	14/967,234
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	14/968,514
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	14/978,976
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS FOR SUSTAINED DELIVERY OF DEXTROMETHORPHAN	14/997,316
COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME	15/014,994
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/042,017
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING PAGET'S DISEASE OF BONE	15/043,141
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/043,281
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	15/043,419
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/055,386
BUPROPION AS A MODULATOR OF DRUG ACTIVITY	15/057,983
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/074,367
OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS	15/074,380
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/083,105
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/130,807
DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	15/136,092



COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	15/164,651
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/164,746
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	15/164,767
THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS	Matter 141- Continuation of U.S. Patent App. No. 14/968,514
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME	Matter 142- Continuation of U.S. Patent App. No. 15/055,386
METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Matter 160- U.S. Non-Provisional of U.S. Prov. Pat. App. No. 62/313,067
METHODS OF MODULATING DRUG PLASMA LEVELS USING BUPROPION	Matter 161- U.S. Non-Provisional of U.S. Prov. Pat. App. Nos. 62/313,620 and 62/323,438
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Matter 187- Continuation-in-Part of U.S. Patent App. No. 14/628,062
COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS	Matter 188- Continuation-in-Part of U.S. Patent App. No. 14/978,976
COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN	Matter 190- Continuation of U.S. Patent App. No. 14/952,724
METHODS OF PREPARING A DOSAGE FORM FOR INCREASING DEXTROMETHORPHAN PLASMA LEVELS	Matter 196- Continuation-in-Part of U.S. Patent App. No. 15/057,983
INPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL	PCT/US2012/037373
COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	PCT/US2013/036836
COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS	PCT/US2013/040939
COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE	PCT/US2014/050427
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN	PCT/US2014/064184
METHODS OF MODULATING DRUG PLASMA LEVELS USING ERYTHROHYDROXYBUPROPION	PCT/US2015/028901
OSTEOCLAST INHIBITORS FOR PAIN	PCT/US2015/032739

ZOLEDRONIC ACID DOSAGE FORMS FOR THE TREATMENT OF PAIN	PCT/US2015/044176
TREATMENT OF PAIN WITH ORAL DOSAGE FORMS COMPRISING ZOLEDRONIC ACID AND AN ENHANCER	PCT/US2015/044190
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM	PCT/US2016/026991
PHARMACODYNAMIC EFFECTS AFTER ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS	PCT/US2016/028807